EXEL250117P13000
- 0.40
- 0.000.00%
Exelixis Newsroom
Brookline Capital Initiates Exelixis(EXEL.US) With Buy Rating, Announces Target Price $40
Express News | Exelixis Inc : Brookline Capital Markets Initiates Coverage With Buy Rating; Target Price $40
Exelixis Shares Decline After BMO Capital Downgrade
BMO Capital Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $40
Do Exelixis' (NASDAQ:EXEL) Earnings Warrant Your Attention?
Express News | Exelixis Inc : BMO Cuts to Market Perform From Outperform
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Peering Into Exelixis's Recent Short Interest
Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Sairopa Reports Research Milestones Achieved in Partnership With Exelixis, Totalling $35 Million From Consecutive Clinical Milestone Payments in 2024
Exelixis Price Target Raised to $39.00/Share From $35.00 by B of A Securities
Exelixis Cut to Neutral From Buy by B of A Securities
Exelixis Analyst Ratings
BofA Securities Downgrades Exelixis(EXEL.US) to Hold Rating, Announces Target Price $39
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Express News | Yuan Si Technology announced that it has received a milestone payment of 10 million dollars from Exelixis.
Exelixis (EXEL) Is an Incredible Growth Stock: 3 Reasons Why
AZN's Bladder Cancer SBLA for Imfinzi Gets FDA's Priority Tag